INCYTE CORPORATION Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
INCYTE CORPORATION (INCY) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $2.23 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-10.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-02-10
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for the quarter ending 2023-12-31 was $282.00K.
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for the quarter ending 2023-09-30 was $3.00M.
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $2.23M, a 10.53% increase from fiscal 2024.
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $2.01M, a 80.60% decline from fiscal 2023.
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $10.38M, a 397.46% increase from fiscal 2022.
- INCYTE CORPORATION unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $2.09M, a 571.06% increase from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 3 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 6 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 9 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|---|---|---|
| 2025-12-31 | $2.23M 10-K · filed 2026-02-10 | |||
| 2024-12-31 | $2.01M 10-K · filed 2026-02-10 | |||
| 2023-12-31 | $282.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | $3.28M derived: sum of 2 quarters · filed 2025-02-10 | $10.38M 10-K · filed 2025-02-10 | |
| 2023-09-30 | $3.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $10.10M 10-Q · filed 2023-10-31 | ||
| 2023-06-30 | $7.10M 10-Q · filed 2023-08-01 | |||
| 2022-12-31 | $2.09M 10-K · filed 2024-02-13 | |||
| 2021-12-31 | $311.00K 10-K · filed 2023-02-07 | |||
| 2020-12-31 | $216.00K 10-K · filed 2022-02-08 | |||
| 2019-12-31 | $82.00K 10-K · filed 2021-02-09 | |||
| 2017-12-31 | $821.00K 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |